China Magnetic Resonance Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

China Magnetic Resonance Imaging Market Trends and Insights

Aging Population & Chronic-Disease Burden

China’s fast-graying society fuels imaging demand as inpatient costs for citizens aged ≥ 65 averaged USD 1,199.24 per stay in 2024 and continue to climb ^{[1]He Shanheng, “Older Adults’ Hospitalization Costs Study in China,” Frontiers in Public Health, frontiersin.org}. Chronic cardiac and neurovascular conditions often require MRI follow-up, and intracranial-aneurysm prevalence of 7%—well above global norms—further concentrates neurologic workload. Tier-1 hospitals respond with high-field upgrades that improve signal-to-noise ratios essential for micro-vascular scans. AI-enabled cardiac MRI now screens 11 cardiovascular pathologies at AUC 0.988 across eight centers, illustrating clinical gains that reinforce adoption. Together these demographic and disease trends lift exam volumes and justify broader capital budgets for next-generation systems.

Expansion of Universal Health Coverage

Commercial medical-insurance premiums reached RMB 900 billion in 2025, complementing public insurance and broadening reimbursement for advanced imaging. Diagnosis-Related Group payment caps cover more than 80% of inpatient expenditure, motivating hospitals to buy faster multipurpose scanners that clear patient backlogs. Rural capsule-clinic pilots rely on portable units that plug into wall outlets and deliver stroke triage accuracy comparable to fixed 1.5 T rooms, bridging access gaps. Together, coverage expansion and flexible reimbursement frameworks extend MRI utilization well beyond metropolitan corridors.

Strong Central-Government Commitments under “Healthy China 2030”

Regulatory reform remains pivotal: the National Medical Products Administration (NMPA) issued twenty-four measures in January 2025 that include parallel reviews and tax credits for innovative devices. Capital subsidies and procurement preferences favor domestic OEMs, aligning with targets to list six Chinese device firms among the global top 50 by 2025. Strategic mergers—such as Neusoft Medical’s state-backed equity infusion—build national champions that can compete overseas and defend local market share.

Adoption of High-/Ultra-High-Field & Hybrid MRI

United Imaging’s FDA-cleared 5 T scanner bridges the gap between mainstream 3 T and research-grade 7 T units, making sub-millimeter neuro-imaging viable in routine practice. Ultra-high-gradient 3 T platforms now finish a prostate study in 5.5 minutes while retaining diagnostic quality. Hybrid PET/MRI continues its oncology base yet gains traction in cardiology and epilepsy care as radiopharmaceutical approvals rise. These upgrades pivot hospitals toward premium modalities that shorten throughput time and enhance precision.

High Capital & Helium-Related Opex

China consumes 25.65 million m³ of helium annually yet produces only 1.3 million m³, driving 95% import dependence. Spot prices have spiked 250% since 2015, squeezing hospital budgets and delaying service contracts. Conventional scanners consume roughly 27% of global helium each year, prompting shutdowns when supply is rationed ^{[2]Henderson Mary, “Keeping an Eye on the Potential Shortage of Helium for MRIs,” RSNA News, rsna.org} . OEMs now race to deploy solid-cooling magnets; Wandong Medical’s helium-free 1.5 T system maintains –269 °C coil temperature while reducing operating costs by more than one-half. These engineering gains mitigate, but do not yet eliminate, cost pressure in lower-tier cities.

Lengthy NMPA Class III Device Approval

Class III MRI devices undergo the most rigorous Chinese review cycle, requiring multi-center trials that prolong market entry. Despite the 2025 reform package, imported models still face longer queues than locally developed units and must establish on-shore quality-management systems before bidding eligibility. The time lag disadvantages foreign vendors in fast-moving procurement rounds and slows technology diffusion to end users eager for the latest software features.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Architecture: Closed Systems Maintain Dominance

Closed units accounted for 82.73% of the China MRI market in 2025 because their higher field strength supports complex neuro-oncologic and cardiac protocols. Throughput pressure and newer algorithms that automate patient positioning now let these sealed tunnels finish a brain scan in as little as 4 minutes. The arrival of wider-bore closed systems further improves patient comfort, eroding historical open-MRI advantages. Open designs nonetheless grow at a 6.02% CAGR as surgeons adopt intra-operative guidance and imaging centers cater to bariatric or claustrophobic populations. Hospitals in secondary cities increasingly buy hybrid models that promise closed-style image fidelity within semi-open form factors, balancing versatility with workflow efficiency.

A parallel engineering trend focuses on helium-free closed magnets, which slash long-term ownership costs and temper supply-chain exposure. Domestic vendors leverage government grants to redesign coil architecture around solid cryogens, strengthening their value proposition in tender documents. As end users weigh capital expenditure against function, closed systems retain the largest slice of the China MRI market size even as architectural preferences diversify.

By Field Strength: Mid-Field Rules, Ultra-High Field Accelerates

Mid/high-field 1-3 T units captured 55.74% of the China MRI market size in 2025 thanks to their clinical versatility and moderate siting requirements. Dual-gradient hardware and AI-driven reconstruction now let 1.5 T scanners rival 3 T detail in some orthopedic tests, protecting installed mid-field bases from immediate obsolescence. Concurrently, ultra-high-field >3 T platforms post a 5.63% CAGR on the back of precision-medicine research, advanced epilepsy mapping, and micro-vasculature imaging in dementia trials. United Imaging’s 5 T entry offers a pragmatic bridge that fits existing suites yet unlocks sub-millimeter resolution, foreshadowing broader ultra-high-field clinical mainstreaming.

Low-field systems, once relegated to niche uses, return to relevance via deep-learning reconstruction that compensates for weaker signal. Whole-body 0.05 T prototypes now produce diagnostic images in open wards without RF-shielded rooms. This resurgence addresses access inequity in county-level hospitals while offering stroke care within ambulance-based units.

By Application: Neurology Leads, Oncology Gains Speed

Neurology contributed 37.92% to the China MRI market share in 2025, mirroring the nation’s disproportionate intracranial-aneurysm and stroke burden. High-resolution vascular sequences and post-processing AI spot sub-3 mm aneurysms often missed by manual reads. Oncology, expanding at a 6.03% CAGR, benefits from aggressive screening programs for lung and colorectal cancer alongside growing PET/MRI adoption for treatment planning. Cardiology pushes AI-enabled CMR into daily practice, achieving near-real-time strain analysis and boosting throughput for ischemic heart-disease clinics. Musculoskeletal and gastroenterology segments also gain from motion-correction software and nanoprobe-based contrast agents that improve liver-fibrosis staging.

By End User: Hospitals Dominate, Imaging Centers Surge

Hospitals owned 47.88% of the China MRI market size in 2025, leveraging bundled procurement contracts and integrated service coverage. DRG-tied reimbursement incentives push tertiary centers to install faster scanners with automated workflows that maximize daily slot turnover. Stand-alone imaging centers, however, advance at 6.18% CAGR as commercial insurance channels reimburse premium studies and entrepreneurs build high-throughput facilities in suburban catchments. Rural mobile clinics and research labs form a smaller but strategic “Others” segment, often adopting portable or specialty coils to satisfy targeted diagnostic needs without heavy infrastructure.

Geography Analysis

Tier-1 cities—Beijing, Shanghai, Guangzhou, and Shenzhen—house the densest concentration of 3 T and above systems, reflecting higher disposable income and research-hospital clusters. Many academic centers place 7 T scanners in dedicated neuroscience wings to study micro-bleeds and small-vessel disease, reinforcing their reputation as technology incubators. Provincial capital hospitals emulate these leaders by purchasing 1.5 T helium-free units that reduce operating costs yet still deliver comprehensive protocol coverage. Migration from rural provinces to coastal megacities maintains imaging volumes and underpins supplementary service contracts.

Tier-2 and tier-3 cities constitute the next adoption wave. Local governments leverage central stimulus grants to modernize medical equipment, prioritizing mid-field scanners that avoid the power-upgrade costs tied to legacy 3 T rooms. Volume-based procurement rounds allow multiple county hospitals to combine orders, driving unit pricing down and reinforcing domestic manufacturers’ competitive edge. As private insurers expand, imaging centers in these cities deploy open configurations that cater to geriatrics and interventional pain management, diversifying revenue channels.

Rural regions still face access gaps, but mobile capsule clinics equipped with 0.23 T stroke-triage systems now bridge distances of hundreds of kilometers. Real-time teleradiology over 5G networks connects village doctors with urban neuroradiologists, ensuring timely interpretation even when staffing is thin. Government “Internet + Healthcare” policies fund these tele-network backbones, and AI triage algorithms further suppress report turnaround time. Over the forecast horizon, balanced regional deployment is expected as domestic OEMs refine ruggedized units suited to China’s vast interior.

Regulatory Landscape

MRI systems are regulated as Class III medical devices in China, with registration review and clinical evaluation overseen by the National Medical Products Administration (NMPA) and its Center for Medical Device Evaluation (CMDE). On June 23, 2026, CMDE issued the Registration Review Guideline for Medical Magnetic Resonance Imaging Systems (2026 Revision) (Announcement No. 21 of 2026), updating technical expectations for areas such as zero-helium architectures, AI-enabled imaging functions, and RF coil configurations. This changes how OEMs prepare product dossiers and plan test and verification.

Policy direction in 2026 also pointed to further streamlining of evidence requirements and standard-setting for MR. On April 30, 2026, NMPA proposed adding permanent magnet, conventional conducting, and superconducting MRI systems to the Clinical Evaluation Exempt Catalog, which can reduce reliance on extensive clinical studies for qualifying configurations. In parallel, the Medical Device Industry Standards Development and Revision Plan published on February 11, 2026 included new and revised standards covering MRI parameters (including spectroscopy-related items), tightening alignment between product specifications, type testing, and procurement eligibility.

Value Chain Analysis

The China MRI value chain covers upstream magnet and cryogenic subsystems (including helium or alternative cooling stacks), gradient amplifiers, RF coils, electronics and software, and shielding and room build-out, followed by system integration, installation, and lifecycle service (maintenance, upgrades, and helium management where applicable). Helium supply remains a structural input risk in the market context, with high import dependence and elevated price volatility. That is accelerating engineering substitution toward sealed, low-helium, and helium-free magnet designs, and increasing the importance of local component sourcing and service capability to control total cost of ownership.

Downstream, commercialization relies on tender participation, distributor and direct-sales coverage for hospitals and imaging centers, and service networks that can meet uptime expectations under DRG-linked throughput pressure. Multinational suppliers continue localizing parts of the chain in China through in-country manufacturing and R&D footprints, for example via Siemens Healthineers localization efforts and GE HealthCare China manufacturing presence referenced in recent coverage. Domestic OEMs then use volume-based procurement dynamics to scale installations and attach bundled service, software, and training to defend margins under price compression.

Market Opportunities and Future Outlook

Regulatory and standards updates in 2026 create whitespace for OEMs that align product roadmaps with China-specific technical expectations, particularly for helium-free or low-helium magnet platforms and AI-enabled imaging functions. The CMDE Registration Review Guideline for Medical Magnetic Resonance Imaging Systems (2026 Revision) dated June 23, 2026, along with the 2026 standards work plan published February 11, 2026, provide clearer compliance and verification goalposts. That supports faster iteration cycles for localized platforms and RF coil portfolios targeted to China tender specifications.

A second opportunity centers on positioning high-end and specialized MRI while building on domestic industrial capability. The NMPA priority review program explicitly includes ultra-high-field MRI systems (>=5T). The NMPA also reported 76 innovative device approvals in 2025, plus 25 priority review approvals (up 212.5% year-on-year), indicating an active channel for differentiated systems and advanced clinical software. On the supply side, actions such as Wandong Medicals third-generation liquid-helium-free MRI launch at CMEF 2026 and Siemens Healthineers localization efforts, including localized MRI lineups, reflect procurement pull and engineering choices converging around operating-cost reduction, localization, and workflow productivity. This is most visible for tier-2/3 hospitals and imaging centers managing reimbursement-driven throughput targets.